The company will compete by continuing product improvements, ramping up marketing presence, and launching an app to improve doctor and consumer engagement.
In a pair of recent studies, Crescendo put forth new clinical utility data and an age and adiposity-adjusted model for its Vectra DA rheumatoid arthritis test.
Siemens Healthineers CEO Bernd Montag talked about the positive impact the firm's Attelica system is having on its revenues, while Bruker discussed plans for the BioTyper platform and assays in the pipeline.
Data from the GUIDED study will be central to commercial payor discussions, a Medicare LCD reconsideration request, and eventually expansion into the primary care market.
